|
|
Volumn 18, Issue 4 Suppl 4, 2002, Pages 20-27
|
|
Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR;
GEFITINIB;
QUINAZOLINE DERIVATIVE;
CANCER STAGING;
DOSE RESPONSE;
DRUG ANTAGONISM;
FEMALE;
FOLLOW UP;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
MALE;
MAXIMUM TOLERATED DOSE;
METHODOLOGY;
MORTALITY;
NEEDLE BIOPSY;
NURSING;
ONCOLOGY NURSING;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
REVIEW;
SURVIVAL;
TREATMENT OUTCOME;
BIOPSY, NEEDLE;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
LUNG NEOPLASMS;
MALE;
MAXIMUM TOLERATED DOSE;
NEOPLASM STAGING;
ONCOLOGIC NURSING;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 0036878749
PISSN: 07492081
EISSN: None
Source Type: Journal
DOI: 10.1053/sonu.2002.37408 Document Type: Review |
|
Times cited : (2)
|
|
References (29)
|
